Infliximab in the treatment of Wegener's granulomatosis: Case report;Infliximab v léčbě Wegenerovy granulomatózy: Kazuistika

Ceska a Slovenska Oftalmologie

Volumn 62, Issue 4, 2006, Pages 280-286

  Svozílková, Petra ^a   Rihova E ^a   Brichova M ^a   Diblik P ^a   Kuthan, P ^a   Poch, T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Infliximab; TNF ; Wegener's granulomatosis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CASE REPORT; CLINICAL FEATURE; DIPLOPIA; DRUG EFFECT; DRUG INFUSION; DRUG MEGADOSE; DRUG RESISTANCE; DRUG TOLERABILITY; EXOPHTHALMOS; EYE MOVEMENT; FOLLOW UP; HUMAN; KIDNEY DISEASE; ORBIT GRANULOMA; PAPILLEDEMA; PARANASAL SINUS DISEASE; REMISSION; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT; WEGENER GRANULOMATOSIS; EYE DISEASE; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY;

ANTIBODIES, MONOCLONAL; EYE DISEASES; HUMANS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; WEGENER GRANULOMATOSIS;

EID: 33745745510     PISSN: 12119059     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Aeberli, D., Oertle, S., Mauron, H., et al.: Inhibition of the TNF pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss. Med. Wkly., 132, 2002: 414-422.
2. Bartolucci, P., Ramanoelina, J., Cohen, P., et al.: Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology, 41, 2002: 1126-1132.
3. Booth, A., Harper, L., Hammad, T., et al.: Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol., 15, 2004: 717-721.
4. Booth, A.D., Jayne, D.R.W., Kharbanda, R.K., et al.: Infliximab improves endothelial dysfunction in systemic vasculitis. A model of vascular inflammation. Circulation, 109, 2004: 1718-1723.
5. Booth, A.D., Jefferson, H.J., Ayliffe, W., et al.: Safety and efficacy of TNFα blockade in relapsing vasculitis. Ann. Rheum. Dis., 61, 2002: 559.
6. Kleinert, J., Lorenz, M., Kostler, W., et al.: Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Wien Klin. Wochenschr., 116, 2004: 334-338.
7. Lamprecht, P., Arbach, O., Voswinkel, J., et al.: Remissionsinduktion mit Infliximab bei therapierefraktärer Wegenerscher Granulomatose- Verlaufsbeobachtung. Dtch. Med. Wochenschr., 127, 2002: 1876-1880.
8. Lamprecht, P., Voswinkel, J., Lilienthal, T., et al.: Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology, 41, 2002: 1303-1307.
9. Pavelka, K.: Biologická léčba revmatoidní artritidy a dalších revmatických onemocnění. Remedia, 1, 2005: 53-66.
10. Rozin, A.: Infliximab efficiency in refractory Wegener's granulomatosis. Rheumatology, 42, 2003: 1124-1125.
11. Volf, V.: Infliximab v terapii chronických záně tlivých onemocnění střevních u dětí a dospívajících. Remedia, 14, 2004: 429-433.